The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: Final results of a single-center prospective clinical trial.
Ming Lu
No relevant relationships to disclose
Xicheng Wang
No relevant relationships to disclose
Zhihao Lu
No relevant relationships to disclose
Jian Li
No relevant relationships to disclose
Jie Li
No relevant relationships to disclose
Yan Li
No relevant relationships to disclose
Xiaotian Zhang
No relevant relationships to disclose
Jun Zhou
No relevant relationships to disclose
Jifang Gong
No relevant relationships to disclose
Jun Jia
No relevant relationships to disclose
Jing Yu
No relevant relationships to disclose
Yan Cui
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose
Xiaodong Zhang
No relevant relationships to disclose